Health Information Exchange (HIE) platform for Kidney Diseases

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Brigham & Women's Hospital, Boston, MA
Kidney Diseases+18 More
Health Information Exchange (HIE) platform - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Sub-optimal transfer of clinical information during inter-hospital transfer (IHT, the transfer of patients between acute care hospitals) is common and can lead to patient harm. To address this problem, the investigators will use key stakeholder input to refine and implement an interoperable health information exchange platform that integrates with the electronic health record and improves the reliability of and access to necessary clinical information in three use cases involving transfer of patients between sending and receiving hospitals with varying levels of affiliation and health record integration. The investigators will assess the effect of this intervention on frequency of medical errors, evaluate the use and usability of this platform from the perspective of those that interact with it, and use these results to develop a dissemination plan to spread implementation and use of this platform across other similar institutions.

Eligible Conditions

  • Kidney Diseases
  • Infections
  • Neurologic Disorders
  • Hematologic Diseases
  • Chronic Obstructive Airways Disease Exacerbated
  • Asthma
  • Arrythmia
  • Heart Failure
  • Critical Illness
  • Oncology Problem
  • Shock
  • Rheumatic Diseases
  • Urologic Diseases
  • Cholera Infantum
  • Kidney Failure
  • Cardiovascular Events

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Kidney Diseases

Study Objectives

1 Primary · 9 Secondary · Reporting Duration: Up to 72-hours after transfer

From time-of-day and date of transfer to time-of-day and date of hospital discharge
Length of stay after transfer
Up to 24-hours after transfer
Time between transferred patient arrival and entry of admission orders
Day 3
Time between acceptance of transfer to patient arrival
Hour 72
Ameliorable clinician-reported adverse events
Clinician-reported medical errors attributable to poor information exchange
Clinician-reported quality of clinical information available
Preventable clinician-reported adverse events
Total clinician-reported adverse events
Total clinician-reported medical errors
Up to 72-hours after transfer
Rapid response or ICU transfer within 72-hours of patient transfer

Trial Safety

Safety Progress

1 of 3

Other trials for Kidney Diseases

Trial Design

2 Treatment Groups

Baseline
1 of 2
Intervention
1 of 2
Active Control
Experimental Treatment

1000 Total Participants · 2 Treatment Groups

Primary Treatment: Health Information Exchange (HIE) platform · No Placebo Group · N/A

Intervention
Other
Experimental Group · 1 Intervention: Health Information Exchange (HIE) platform · Intervention Types: Other
BaselineNoIntervention Group · 1 Intervention: Baseline · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 72-hours after transfer

Trial Background

Stephanie Mueller, Associate Physician
Principal Investigator
Brigham and Women's Hospital
Closest Location: Brigham & Women's Hospital · Boston, MA
Photo of Boston  1Photo of Boston  2Photo of Boston  3
2001First Recorded Clinical Trial
8 TrialsResearching Kidney Diseases
163 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are transferred from one of the 3 hospitals.
You must be at least 18 years old to participate in this study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.